Home›Atenolol›Atenolol + Glycopyrrolate Oral Solution

Does Atenolol Interact with Glycopyrrolate Oral Solution?

CDI records a moderate classification for Atenolol and Glycopyrrolate Oral Solution. The stored summary is: Atenolol bioavailability may be increased with glycopyrrolate coadministration. Reduction in atenolol dose may be needed. The mechanism involves increased bioavailability. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification
Moderate
Atenolol Class
beta-Adrenergic Blocker
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Increased bioavailability

What To Tell Your Doctor or Pharmacist

If you are taking Atenolol and your doctor is considering prescribing Glycopyrrolate Oral Solution (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Atenolol(Tenormin)+💊 Glycopyrrolate Oral Solution(Cuvposa)

Severity & Interaction Details

🟡
moderate
Stored CDI classification: moderate
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
beta-Adrenergic Blocker
Drug B class
—
Source
NLP:glycopyrrolate oral solution

What this means in plain English

Atenolol bioavailability may be increased with glycopyrrolate coadministration. Reduction in atenolol dose may be needed.

About Atenolol and Glycopyrrolate Oral Solution

Atenolol is a beta-Adrenergic Blocker. You may recognize them by the brand names Tenormin and Cuvposa. Atenolol additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:glycopyrrolate oral solution

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Atenolol and Glycopyrrolate Oral Solution against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations